Small molecule inhibitors targeting both the IR and IGF1R or blockading beta‐adrenergic receptor‐mediated insulin‐like growth factor receptor activation could reduce NSCLC cell proliferation and prevent LC [49, 50]. This evidence concerns the gene IGF1R and laryngotracheoesophageal cleft.